HUTCHMED (NASDAQ:HCM) Raised to “Strong-Buy” at Jefferies Financial Group

HUTCHMED (NASDAQ:HCM) was upgraded by equities researchers at Jefferies Financial Group to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Other research analysts have also recently issued research reports about the company. Wall Street Zen upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Morgan Stanley lowered shares of HUTCHMED from an “equal weight” rating to an “underweight” rating and decreased their price target for the company from $18.00 to $13.75 in a report on Monday, September 22nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $20.88.

HUTCHMED Stock Performance

Shares of NASDAQ HCM opened at $15.62 on Monday. The business’s 50 day moving average price is $14.19 and its two-hundred day moving average price is $15.43. HUTCHMED has a twelve month low of $11.51 and a twelve month high of $19.50. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.65 and a quick ratio of 4.51.

Institutional Trading of HUTCHMED

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Blue Trust Inc. boosted its position in HUTCHMED by 131.5% in the fourth quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after purchasing an additional 4,378 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its position in shares of HUTCHMED by 23.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock valued at $233,000 after purchasing an additional 2,916 shares in the last quarter. Ameriprise Financial Inc. grew its position in HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after buying an additional 698 shares in the last quarter. Bank of America Corp DE boosted its position in shares of HUTCHMED by 17.3% during the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after acquiring an additional 3,035 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in HUTCHMED by 34.2% during the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after purchasing an additional 5,538 shares during the last quarter. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.